Acute vasoconstriction-induced insulin resistance in rat muscle in vivo

Diabetes

Volumn 48, Issue 3, 1999, Pages 564-569

  Rattigan, Stephen ^a   Clark, Michael G ^a   Barrett, Eugene J ^b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW VELOCITY; CAPILLARY FLOW; GLUCOSE TRANSPORT; HINDLIMB; INSULIN RESISTANCE; MALE; MUSCLE BLOOD FLOW; MUSCLE METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION;

EID: 0032972029     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.48.3.564     Document Type: Article

References (48)

1. Baron AD: Hemodynamic actions of insulin. Am J Physiol 267:E187-E202, 1994
2. Baron AD: Nitric oxide mediates skeletal glucose transport (Reply). Am J Physiol 270:E1058-E1059, 1996
3. Chen YL, Messina EJ: Dilation of isolated skeletal muscle arterioles by insulin is endothelium dependent and nitric oxide mediated. Am J Physiol 270:H2120-H2124, 1996
4. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P: Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 94:2511-2515, 1994
5. 15O]CO and positron emission tomography. Am J Physiol 269:E1000-E1005, 1995
6. Rattigan S, Clark MG, Barrett EJ: Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. Diabetes 46:1381-1388, 1997
7. Baron AD, Laakso M, Brechtel G, Hoit B, Watt C, Edelman SV: Reduced post-prandial skeletal muscle blood flow contributes to glucose intolerance in human obesity. J Cin Endocrinol Metab 70:1525-1533, 1990
8. Baron AD, Laakso M, Brechtel G, Edelman SV: Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab 73:637-643, 1991
9. Baron AD, Brechtel-Hook G, Johnson A, Hardin D: Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 21:129-135, 1993
10. Laakso M, Edelman SV, Brechtel G, Baron AD: Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes 41:1076-1083, 1992
11. Meneilly GS, Elliot T, Bryer-Ash M, Floras JS: Insulin-mediated increase in blood flow is impaired in the elderly. J Clin Endocrinol Metab 80:1899-1903, 1995
12. Baron AD: Insulin and the vasculature: old actors, new roles. J Invest Med 44:406-412, 1996
13. Baron AD, Clark MG: Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr 17:487-499, 1997
14. Baron AD: The coupling of glucose metabolism and perfusion in human skeletal muscle: the potential role of endothelium-derived nitric oxide. Diabetes 45 (Suppl. 1):S105-S109, 1996
15. Clark MG, Colquhoun EQ, Rattigan S, Dora KA, Eldershaw TP, Hall JL, Ye J: Vascular and endocrine control of muscle metabolism (Review). Am J Physiol 268:E797-E812, 1995
16. Dora KA, Richards SM, Rattigan S, Colquhoun EQ, Clark MG: Serotonin and norepinephrine vasoconstriction in rat hindlimb have different oxygen requirements. Am J Physiol 262:H698-H703, 1992
17. Newman JMB, Dora KA, Rattigan S, Edwards SJ, Colquhoun EQ, Clark MG: Norepinephrine and serotonin vasoconstriction in rat hindlimb control different vascular flow routes. Am J Physiol 270:E689-E699, 1996
18. Rattigan S, Appleby GJ, Miller KA, Steen JT, Dora KA, Colquhoun EQ, Clark MG: Serotonin inhibition of 1-methylxanthine metabolism parallels inhibition of oxygen uptake in perfused rat hindlimb. Acta Physiol Scand 161:161-169, 1997
19. Rattigan S, Dora KA, Colquhoun EQ, Clark MG: Inhibition of insulin-mediated glucose uptake in rat hindlimb by an α-adrenergic vascular effect. Am J Physiol 268:E305-E311, 1995
20. Rattigan S, Dora KA, Colquhoun EQ, Clark MG: Serotonin-mediated acute insulin resistance in the perfused rat hindlimb but not in incubated muscle: a role for the vascular system. Life Sci 53:1545-1555, 1993
21. Parks DA, Granger DN: Xanthine oxidase: biochemistry, distribution and physiology (Review). Acta Physiol Scand 548 (Suppl.):87-99, 1986
22. Jarasch ED, Bruder G, Heid HW: Significance of xanthine oxidase in capillary endothelial cells. Acta Physiol Scand 548 (Suppl.):39-46, 1986
23. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203, 1994
24. Baudrie V, Chaouloff F: Mechanisms involved in the hyperglycemic effect of the 5-HT1C/5-HT2 receptor agonist. DOI. Eur J Pharmacol 213:41-46, 1992
25. Newman JMB, Clark MG: Stimulation and inhibition of resting muscle thermogenesis by vasoconstrictors in perfused rat hindlimb. Can J Physiol Pharmacol. (In press)
26. Emmerson BT, Gordon RB, Cross M, Thomson DB: Plasma oxipurinol concentrations during allopurinol therapy Br J Rheumatol 26:445-449, 1987
27. Wynants J, Petrov B, Nijhof J, Van Belle H: Optimization of a high-performance liquid chromatographic method for the determination of nucleosides and their catabolites: application to cat and rabbit heart perfusates. J Chromatogr 386:297-308, 1987
28. Chaouloff F, Laude D, Baudrie V: Effects of the 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur J Pharmacol 187:435-443, 1990
29. Chaouche-Teyara K, Fournier B, Safar M, Dabire H: Systemic and regional haemodynamic effects of 1-(2,5-dimethoxy-4-iodo-phenyl)-2-aminopropane (DOI) and alpha-methyl-5-HT, in the anaesthetised rat. Clin Exp Hypertens 16:779-798, 1994
30. Blackshear JL, Orlandi C, Garnic JD, Hollenberg NK: Differential large and small vessel responses to serotonin in the dog hindlimb in vivo: role of the 5HT2 receptor. J Cardiovasc Pharmacol 7:42-19, 1985
31. Van Zwieten PA, Blauw GJ, van Brummelen P: The role of 5-hydroxytryptamine and 5-hydroxytryptaminergic mechanisms in hypertension. Br J Clin Pharmacol 30 (Suppl 1):69S-74S, 1990
32. Schiffrin EL: The endothelium and control of blood vessel function in health and disease. Clin Invest Med 17:602-620, 1994
33. James DE, Burleigh KM, Storlien LH, Bennett SP, Kraegen EW: Heterogeneity of insulin action in muscle: influence of blood flow. Am J Physiol 251:E422-E430, 1986
34. Baron AD, Brechtel G: Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol 265:E61-E67, 1993
35. Vierhapper H, Gasic S, Roden M, Waldhausl W: Increase in skeletal muscle blood flow but not in renal blood flow during euglycemic hyperinsulinemia in man. Horm Metab Res 25:438-441, 1993
36. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87:2246-2252, 1991
37. Utriainen T, Malmström R, Mäkimattila S, Yki-Järvinen H: Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects. Diabetologia 38:555-564, 1995
38. Vollenweider L, Tappy L, Owlya R, Jéquier E, Nicod P, Scherrer U: Insulin-induced sympathetic activation and vasodilation in skeletal muscle: effects of insulin resistance in lean subjects. Diabetes 44:641-645, 1995
39. Feldman RD, Bierbrier GS: Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet 342:707-709, 1993
40. Fujishima S, Imaizumi T, Abe I, Takeshita A, Fujishima M: Effects of intra-arterial infusion of insulin on forearm vasoreactivity in hypertensive humans. Hypertens Res 18:227-233, 1995
41. Gudbjörnsdottir S, Elam M, Sellgren J, Anderson EA: Insulin increases forearm vascular resistance in obese, insulin-resistant hypertensives. J Hypertens 14:91-97, 1996
42. Hunter SJ, Harper R, Ennis CN, Sheridan B, Atkinson AB, Bell PM: Skeletal muscle blood flow is not a determinant of insulin resistance in essential hypertension. J Hypertens 15:73-77, 1997
43. Bruning TA, Chang PC, Blauw GJ, Vermeij P, Van Zwieten PA: Serotonin-induced vasodilatation in the human forearm is mediated by the "nitric oxide-pathway": no evidence for involvement of the 5-HT3-receptor. J Cardiovasc Pharmacol 22:44-51, 1993
44. Lamping KG, Kanatsuka H, Eastham CL, Chilian WM, Marcus ML: Nonuniform vasomotor responses of the coronary microcirculation to serotonin and vasopressin. Circ Res 65:343-351, 1989
45. Wilmoth FR, Harris PD, Miller FN: Differential serotonin responses in the skeletal muscle microcirculation. Life Sci 34:1135-1141, 1984
46. Hollenberg NK: Large and small vessel responses to serotonin in the peripheral circulation. J Cardiovasc Pharmacol 7 (Suppl. 7):S89-S91, 1985
47. Dora KA, Rattigan S, Colquhoun EQ, Clark MG: Aerobic muscle contraction impaired by serotonin-mediated vasoconstriction. J Appl Physiol 77:277-284, 1994
48. Buchanan TA, Thawani H, Kades W, Modrall JG, Weaver FA, Laurel C, Poppiti R, Xiang A, Hseuh W: Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. J Clin Invest 92:720-726, 1993